213 related articles for article (PubMed ID: 28522924)
1. Use of the 4Kscore test to predict the risk of aggressive prostate cancer prior to prostate biopsy: Overall cost savings and improved quality of care to the us healthcare system.
Voigt JD; Dong Y; Linder V; Zappala S
Rev Urol; 2017; 19(1):1-10. PubMed ID: 28522924
[TBL] [Abstract][Full Text] [Related]
2. The 4Kscore® Test Reduces Prostate Biopsy Rates in Community and Academic Urology Practices.
Konety B; Zappala SM; Parekh DJ; Osterhout D; Schock J; Chudler RM; Oldford GM; Kernen KM; Hafron J
Rev Urol; 2015; 17(4):231-40. PubMed ID: 26839521
[TBL] [Abstract][Full Text] [Related]
3. Finding the Wolf in Sheep's Clothing: The 4Kscore Is a Novel Blood Test That Can Accurately Identify the Risk of Aggressive Prostate Cancer.
Punnen S; Pavan N; Parekh DJ
Rev Urol; 2015; 17(1):3-13. PubMed ID: 26028995
[TBL] [Abstract][Full Text] [Related]
4. Implementation of 4Kscore as a Secondary Test Before Prostate Biopsy: Impact on US Population Trends for Prostate Cancer.
Scuderi S; Tin A; Gandaglia G; Stabile A; Montorsi F; Briganti A; Vickers AJ
Eur Urol Open Sci; 2023 Jun; 52():1-3. PubMed ID: 37182119
[TBL] [Abstract][Full Text] [Related]
5. Reducing unnecessary biopsies while detecting clinically significant prostate cancer including cribriform growth with the ERSPC Rotterdam risk calculator and 4Kscore.
Verbeek JFM; Bangma CH; Kweldam CF; van der Kwast TH; Kümmerlin IP; van Leenders GJLH; Roobol MJ
Urol Oncol; 2019 Feb; 37(2):138-144. PubMed ID: 30528698
[TBL] [Abstract][Full Text] [Related]
6. A multi-institutional prospective trial in the USA confirms that the 4Kscore accurately identifies men with high-grade prostate cancer.
Parekh DJ; Punnen S; Sjoberg DD; Asroff SW; Bailen JL; Cochran JS; Concepcion R; David RD; Deck KB; Dumbadze I; Gambla M; Grable MS; Henderson RJ; Karsh L; Krisch EB; Langford TD; Lin DW; McGee SM; Munoz JJ; Pieczonka CM; Rieger-Christ K; Saltzstein DR; Scott JW; Shore ND; Sieber PR; Waldmann TM; Wolk FN; Zappala SM
Eur Urol; 2015 Sep; 68(3):464-70. PubMed ID: 25454615
[TBL] [Abstract][Full Text] [Related]
7. Budget impact model: epigenetic assay can help avoid unnecessary repeated prostate biopsies and reduce healthcare spending.
Aubry W; Lieberthal R; Willis A; Bagley G; Willis SM; Layton A
Am Health Drug Benefits; 2013 Jan; 6(1):15-24. PubMed ID: 24991343
[TBL] [Abstract][Full Text] [Related]
8. Avoiding Unnecessary Magnetic Resonance Imaging (MRI) and Biopsies: Negative and Positive Predictive Value of MRI According to Prostate-specific Antigen Density, 4Kscore and Risk Calculators.
Falagario UG; Martini A; Wajswol E; Treacy PJ; Ratnani P; Jambor I; Anastos H; Lewis S; Haines K; Cormio L; Carrieri G; Rastinehad AR; Wiklund P; Tewari A
Eur Urol Oncol; 2020 Oct; 3(5):700-704. PubMed ID: 31548130
[TBL] [Abstract][Full Text] [Related]
9. The 4Kscore blood test accurately identifies men with aggressive prostate cancer prior to prostate biopsy with or without DRE information.
Zappala SM; Dong Y; Linder V; Reeve M; Sjoberg DD; Mathur V; Roberts R; Okrongly D; Newmark J; Sant G; Steiner M
Int J Clin Pract; 2017 Jun; 71(6):. PubMed ID: 28497893
[TBL] [Abstract][Full Text] [Related]
10. Performance of 4Kscore as a Reflex Test to Prostate-specific Antigen in the GÖTEBORG-2 Prostate Cancer Screening Trial.
Josefsson A; Månsson M; Kohestani K; Spyratou V; Wallström J; Hellström M; Lilja H; Vickers A; Carlsson SV; Godtman R; Hugosson J
Eur Urol; 2024 May; ():. PubMed ID: 38772787
[TBL] [Abstract][Full Text] [Related]
11. Optimizing patient's selection for prostate biopsy: A single institution experience with multi-parametric MRI and the 4Kscore test for the detection of aggressive prostate cancer.
Punnen S; Nahar B; Soodana-Prakash N; Koru-Sengul T; Stoyanova R; Pollack A; Kava B; Gonzalgo ML; Ritch CR; Parekh DJ
PLoS One; 2018; 13(8):e0201384. PubMed ID: 30092002
[TBL] [Abstract][Full Text] [Related]
12. The effect of digital rectal exam on the 4Kscore for aggressive prostate cancer.
Maccini MA; Westfall NJ; Van Bokhoven A; Lucia MS; Poage W; Maroni PD; Wilson SS; Glodé LM; Arangua P; Newmark J; Steiner M; Werahera PN; Crawford ED
Prostate; 2018 May; 78(7):506-511. PubMed ID: 29460452
[TBL] [Abstract][Full Text] [Related]
13. Clinical performance of the 4Kscore Test to predict high-grade prostate cancer at biopsy: A meta-analysis of us and European clinical validation study results.
Zappala SM; Scardino PT; Okrongly D; Linder V; Dong Y
Rev Urol; 2017; 19(3):149-155. PubMed ID: 29302237
[TBL] [Abstract][Full Text] [Related]
14. A Preliminary Study of the Ability of the 4Kscore test, the Prostate Cancer Prevention Trial-Risk Calculator and the European Research Screening Prostate-Risk Calculator for Predicting High-Grade Prostate Cancer.
Borque-Fernando Á; Esteban-Escaño LM; Rubio-Briones J; Lou-Mercadé AC; García-Ruiz R; Tejero-Sánchez A; Muñoz-Rivero MV; Cabañuz-Plo T; Alfaro-Torres J; Marquina-Ibáñez IM; Hakim-Alonso S; Mejía-Urbáez E; Gil-Fabra J; Gil-Martínez P; Ávarez-Alegret R; Sanz G; Gil-Sanz MJ
Actas Urol Esp; 2016 Apr; 40(3):155-63. PubMed ID: 26598800
[TBL] [Abstract][Full Text] [Related]
15. A 4Kscore Cut-off of 7.5% for Prostate Biopsy Decisions Provides High Sensitivity and Negative Predictive Value for Significant Prostate Cancer.
Bhattu AS; Zappala SM; Parekh DJ; Punnen S
Urology; 2021 Feb; 148():53-58. PubMed ID: 33217456
[TBL] [Abstract][Full Text] [Related]
16. Prospective validation of microseminoprotein-β added to the 4Kscore in predicting high-grade prostate cancer in an international multicentre cohort.
Lonergan PE; Vertosick EA; Assel M; Sjoberg DD; Haese A; Graefen M; Boorjian SA; Klee GG; Cooperberg MR; Pettersson K; Routila E; Vickers AJ; Lilja H
BJU Int; 2021 Aug; 128(2):218-224. PubMed ID: 33306251
[TBL] [Abstract][Full Text] [Related]
17. Clinical Utility of 4Kscore
de la Calle CM; Fasulo V; Cowan JE; Lonergan PE; Maggi M; Gadzinski AJ; Yeung RA; Saita A; Cooperberg MR; Shinohara K; Carroll PR; Nguyen HG
J Urol; 2021 Feb; 205(2):452-460. PubMed ID: 32897802
[TBL] [Abstract][Full Text] [Related]
18. The 4Kscore Predicts the Grade and Stage of Prostate Cancer in the Radical Prostatectomy Specimen: Results from a Multi-institutional Prospective Trial.
Punnen S; Nahar B; Prakash NS; Sjoberg DD; Zappala SM; Parekh DJ
Eur Urol Focus; 2017 Feb; 3(1):94-99. PubMed ID: 28720374
[TBL] [Abstract][Full Text] [Related]
19. Developing an effective strategy to improve the detection of significant prostate cancer by combining the 4Kscore and multiparametric MRI.
Marzouk K; Ehdaie B; Vertosick E; Zappala S; Vickers A
Urol Oncol; 2019 Oct; 37(10):672-677. PubMed ID: 31378585
[TBL] [Abstract][Full Text] [Related]
20. Predicting Grade group 2 or higher cancer at prostate biopsy by 4Kscore in blood and uCaP microRNA model in urine.
Fredsøe J; Rasmussen M; Tin AL; Vickers AJ; Borre M; Sørensen KD; Lilja H
Sci Rep; 2022 Sep; 12(1):15193. PubMed ID: 36071094
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
